SNSE - Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action Pharmacokinetic Profile and Safety Characteristics for SNS-101 a Conditionally Active VISTA-blocking Antibody at the Seventh CRI-ENCI-AACR International Cancer Immuno
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 20 – 23, 2023 in Milan, Italy. The new data build on SNS-101's preclinical safety and efficacy profile and provide additional insights into its conditionally active mechanism of action. SNS-101 is currently in a Phase 1/2 clinical study.
Presentation Details:
Title: SNS-101, a clinical-stage pH-dependent and TME-selective anti-VISTA antibody with favorable pharmacokinetic and safety characteristics, promotes anti-tumoral M1 macrophage polarization in PD-1 refractory settings
Presentation Type: Poster
Date and Time: Thursday, September 21, 2023, from 12:30 pm to 2:00 pm CET
Session: Poster Session A
The poster will be made available on the Sensei Bio website following the presentation.
About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ:SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable ...